Clinical trial Recruiting at 1 site Phase 1 Interventional Ages 18 to 40

Recording nerve activity from the vagus nerve in awake individuals

Official title: Microelectrode Recordings From the Vagus Nerve in Awake Humans

Run by University of Minnesota · NCT06016686 · Data updated 2026-11-12

This study is testing how different settings of vagus nerve stimulation affect nerve activity in awake people who have VNS devices, to better understand how the nerve works.

More Epilepsy trials

Quick facts

PhasePhase 1
Study typeInterventional
Ages18 Years to 40 Years
SexAll
Enrollment60 (estimated)
SponsorUniversity of Minnesota
Academic / other
Locations1 site (Minneapolis, Minnesota)
StatusRecruiting
StartedApril 1, 2024
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedApril 20, 2026
Trial IDNCT06016686 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are English-speaking individuals aged 18 to 40 with Medicare or equivalent health insurance.

Probably not a fit

Patients who are pregnant, smoke and cannot abstain, or have significant carotid artery issues may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project utilizes a refined technique of ultrasound-guided microneurography to investigate the human cervical vagus nerve in awake participants. The study aims to gather detailed neurophysiological data on the vagus nerve and identify which nerve fibers are activated during vagal nerve stimulation (VNS) in individuals with implanted VNS devices. By varying stimulation parameters such as intensity, duration, and frequency, the research seeks to differentiate the responses of myelinated and unmyelinated nerve fibers. The findings will contribute to the development of novel neural interfaces for VNS and enhance understanding of its clinical applications.

Why it matters

Potential benefit: If successful, this study could lead to improved VNS therapies for epilepsy and other conditions.

How similar studies have gone: Previous studies using similar techniques have been conducted safely, indicating potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* The participant is greater than or equal to (≥)18 years and is less than or equal to (≤) 40 years of age
* English speaking
* Medicare covered or equivalent health insurance from a partner country

Exclusion Criteria:

* Pregnant
* Smokes and is unwilling to abstain from smoking on the day of the experiment.
* Inability or unwillingness to provide written informed consent.
* Individuals with difficulty standing unassisted for 5 minutes during the tilt-table testing
* Individuals found to have a significant carotid artery plaque or intima-media thickness \> 1 mm as assessed by ultrasonography during the ultrasound-screening steps of the study visit
* Vagus nerve not visible on ultrasound
* VNS electrodes are not in a suitable location to allow for microelectrode insertion
* Any other clinical reasons deemed by the investigators

Where it's running

  • University of Minnesota
    Minneapolis, Minnesota, United States
    Recruiting

Study contacts

  • Principal investigator: Vaughan G Macefield, PhD — Monash University
  • Study coordinator: Kathryn Vera, PhD
  • Email: giero002@umn.edu
  • Phone: 612-625-5018

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.